급성 흥분 및 공격성 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Acute Agitation And Aggression Treatment Market is presumed to reach the market size of nearly USD 8.02 Billion by 2032 from USD 4.85 Billion in 2023 with a CAGR of 5.75% under the study period 2024-2032.

Acute Agitation refers to the state of inner tension or unease with or without abnormal motor activity. While acute aggression signifies a behavioural expression with the potential to self-harm or harm others. Acute agitation and aggressive treatment are nothing but the medical care given to a patient to get cured of agitation and aggression. Generally, acute agitation and aggression are caused in an individual due to reasons like depression, bipolar disorder, alcohol dependency, hormonal imbalances, autism, stress, and neurological disorders. Acute agitation and aggression treatment can help in restoring the sense of calm.

MARKET DYNAMICS

The global acute agitation and aggression treatment market is gaining popularity owing to the rise in the agitation and aggression diagnosis in psychological illnesses, the increase in the economic burden of psychological illness, and the formation of an organization to spread awareness. Altering attitudes toward agitation and aggression diagnosis among mentally ill patients and an increase in awareness about treatments are likely to fuel the global acute agitation and aggression treatment market growth. Additionally, research and development of novel treatments for acute agitation and aggression are expected to drive market growth. The rise in mental illness, increase in dementia incidences among the geriatric population, the rush in agitation in patients, and an increase in prescriptions of anti-psychotics are boosting the growth of the acute agitation and aggression treatment market in the forthcoming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Agitation And Aggression Treatment. The growth and trends of Acute Agitation And Aggression Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Agitation And Aggression Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Approach

• Behavioral Approaches
• Environmental Interventions
• Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others)

By Indication

• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Drug-induced Agitation and Aggression
• Alcohol Withdrawal
• Others

By Route of Administration

• Oral
• Intramuscular
• Others

By End User

• Hospitals & Ambulatory Surgical Centers
• Psychiatric Care Facilities
• Others
• Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Global Acute Agitation And Aggression Treatment Market Report market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Agitation And Aggression Treatment market include Eli Lilly And Company, Pfizer Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ACUTE AGITATION AND AGGRESSION TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment Approach
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By End User
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY TREATMENT APPROACH

• 5.1. Overview By Treatment Approach
• 5.2. Historical and Forecast Data Analysis By Treatment Approach
• 5.3. Behavioral Approaches Historic and Forecast Sales By Regions
• 5.4. Environmental Interventions Historic and Forecast Sales By Regions
• 5.5. Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Historic and Forecast Sales By Regions

6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY INDICATION

• 6.1. Overview By Indication
• 6.2. Historical and Forecast Data Analysis By Indication
• 6.3. Schizophrenia Historic and Forecast Sales By Regions
• 6.4. Dementia Historic and Forecast Sales By Regions
• 6.5. Bipolar Disorder Historic and Forecast Sales By Regions
• 6.6. Depression Historic and Forecast Sales By Regions
• 6.7. Drug-induced Agitation and Aggression Historic and Forecast Sales By Regions
• 6.8. Alcohol Withdrawal Historic and Forecast Sales By Regions
• 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route of Administration
• 7.2. Historical and Forecast Data Analysis By Route of Administration
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Intramuscular Historic and Forecast Sales By Regions
• 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY END USER

• 8.1. Overview By End User
• 8.2. Historical and Forecast Data Analysis By End User
• 8.3. Hospitals & Ambulatory Surgical Centers Historic and Forecast Sales By Regions
• 8.4. Psychiatric Care Facilities Historic and Forecast Sales By Regions
• 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ACUTE AGITATION AND AGGRESSION TREATMENT COMPANIES

• 10.1. Acute Agitation And Aggression Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF ACUTE AGITATION AND AGGRESSION TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Eli Lilly And Company
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Pfizer Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Otsuka Holdings
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. GlaxoSmithKline
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. H. Lundbeck A/S
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Johnson & Johnson
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Teva Pharmaceutical Industries Ltd.
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Amneal Pharmaceuticals LLC
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Sun Pharmaceutical Industries Ltd.
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. F. Hoffmann-La Roche Ltd
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Bausch Health Companies Inc.
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Apotex Inc.
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. Aurobindo Pharma
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies